TNFRSF9 and neoplasm: To minimize residual anti-4-1BB mAb in the mice, those with 100–200 mm3 tumor tissues were selected on day 23 (7 days after last Ab injection) and further treated with rat IgG or anti-PD-1 mAb every 5 days.